AFP Tumor Marker
| Abbrev Code: | FETO | ||
| Order Code: | LAB559 | Order Name: | AFP Tumor Marker |
| Methodology: | Roche: Electrochemiluminescence immunoassay (ECLIA) | ||
| CPT Codes: | 82105 x1, 82105 x1 | ||
| Turnaround Time: | Performed and reported 24 hours/day. | ||
| Special Instructions: | This test is used as a tumor marker, not for neural tube defect screening. | ||
| Associated Links: | |||
Collection Instructions
| Specimen: | Blood |
| Optimal Volume: | 2.5 mL |
| Minimum\Peds Volume: | 0.6 mL |
| Container: | Green (lithium heparin, gel) Alternate Containers: Green (lithium heparin, no gel), Green (lithium heparin) on ICE, Red (no gel), Red or gold (gel) |
| Collection Instructions: | Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration. |
| Causes for Rejection: | Gross hemolysis |
Processing and Shipping
| Specimen Processing: | Centrifuge and aliquot 1.25 mL, 0.2 mL minimum. Store in refrigerator. |
| Shipping Instructions: | Ship at refrigerated temperature. |
| Stability: | 5 days at room temperature; 14 days refrigerated; 6 months frozen. Samples may be frozen 3 times. |
| Test Performed at or Referral Lab | Chemistry (Roche-UMMC East) |
Interpretive
| Reference Range: | <=8.3 ng/mL
AFP values vary depending on the testing procedure used. Therefore, the result must always contain a statement on the AFP assay method used. If there is a change in the AFP assay procedure used while monitoring therapy, then the AFP values obtained upon changing over to the new procedure must be confirmed by parallel measurements with both methods. |
| Use: | Immunoassay for the in vitro quantitative determination of α1-fetoprotein in human serum and plasma to aid in the management of patients with non-seminomatous germ cell tumors. |
Click HERE to Report test errors or omissions.
*If no email program is associated with this computer, please contact:
systemlabguide@fairview.org for TestID: 496"